BenevolentAI
the benevolent platform is and commercially validated and has already delivered asset in phase assets in exploratory stage programmes a leading covid treatment that is now approved successful target collaboration with further validates our approach with a total of novel targets selected for portfolio well funded with key value in points in the near and medium term scientifically | BenevolentAI
Company
Deck Type
Deck date
September 2022
Slide
5 of 74
Similar slides by BenevolentAI
Investor Conference
January 2023
Investor Conference
November 2022
Investor Presentation
October 2022
Other recent decks by BenevolentAI
Results
March 2024
Investor Conference
January 2024
Investor Presentation
May 2023
Results
March 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2023 Slidebook.io